Sugi Predict

Sugi Predict / Compounds / SCHEMBL4194067

SCHEMBL4194067

SCHEMBL4194067

COc1ccc(S(=O)(=O)N2C[C@@H](C)N(S(=O)(=O)c3ccc(OC)c(OC)c3)[C@@H](C)C2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ PKM P14618 3/20 0.51
▸ PKLR P30613 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ LMNA P02545 4/20 0.50
▸ HTT P42858 2/20 0.48
▸ GLA P06280 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ USP2 O75604 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4181445 0.94 GPBAR1 (0.61) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL4183520 0.94 GPBAR1 (0.61) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL4187163 0.94 GPBAR1 (0.61) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL14384041 0.94 GPBAR1 (0.61) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL4184715 0.94 GPBAR1 (0.61) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL4174617 0.89 GPBAR1 (0.51) GPBAR1SMN1; SMN2PKMPKLRALDH1A1
SCHEMBL4174514 0.89 GPBAR1 (0.51) GPBAR1SMN1; SMN2PKMPKLRALDH1A1
SCHEMBL4187473 0.88 GPBAR1 (0.54) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL4176441 0.86 GPBAR1 (0.53) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4
SCHEMBL4186375 0.86 GPBAR1 (0.53) GPBAR1SMN1; SMN2PKMALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US claimed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 — — EP claimed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 — — WO claimed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 — — EP disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A GPBAR1 81/4885SMN1; SMN2 1624/4885PKM 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.